Clinical Trials

40 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03725436 2026-03-16

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

28 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01303497 2026-03-13

ANGIO-TAX+

70 enrolled

Sarcoma

Hemangiosarcoma

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT03976362 2026-02-25

KEYLYNK-008

851 enrolled 25 charts

Tumor-Agnostic

Carcinoma

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

712 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

41 enrolled 9 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01853748 2026-02-19

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

512 enrolled 28 charts

Breast Neoplasms

NCT02513563 2026-02-19

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

42 enrolled 12 charts

Lung Neoplasms

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

203 enrolled 22 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07307911 2026-02-13

Co-Pa-N

50 enrolled

Breast Neoplasms

NCT02195973 2026-02-09

Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

15 enrolled

Ovarian Neoplasms

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

121 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

23 enrolled 10 charts

Breast Neoplasms

NCT05226598 2026-02-05

MK-7684A-007

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03884101 2026-02-02

LEAP-001

842 enrolled 25 charts

Endometrial Neoplasms

NCT03798626 2026-01-27

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

GastrointestinalGenitourinary

167 enrolled

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT03829722 2026-01-22

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

26 enrolled 13 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06513364 2026-01-20

Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 1 FDA

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Completed

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00980954 2025-12-31

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

236 enrolled 28 charts

Uterine Cervical Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT02001272 2025-12-19

EWOC-1

120 enrolled